This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ting, A. Y. Articles by Petroff, B. K. Search for Related Content PubMed PubMed Citation Articles by Ting, A. Y. Articles by Petroff, B. K. Related Collections Preclinical Intervention Preclinical Intervention: In Vivo (Animals): Drugs, Nutritional Interventions, Mechanisms

Tamoxifen Prevents Premalignant Changes of Breast, but not Ovarian, Cancer in Rats at High Risk for Both Diseases

Authors' Affiliations: ¹ Breast Cancer Prevention Center, Departments of ² Molecular and Integrative Physiology, ³ Internal Medicine, and ⁴ Radiation Oncology, and ⁵ Center for Reproductive Sciences, University of Kansas Medical Center, Kansas City, Kansas

Requests for reprints: Brian Petroff, Department of Internal Medicine, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160. Phone: 913-588-3992; Fax: 913-588-3821; E-mail: bpetroff{at}kumc.edu.

Women at increased risk for breast cancer are at increased risk for ovarian cancer as well, reflecting common risk factors and intertwined etiology of the two diseases. We previously developed a rat model of elevated breast and ovarian cancer risk, allowing evaluation of dual-target cancer prevention strategies. Tamoxifen, a Food and Drug Administration–approved breast cancer chemoprevention drug, has been shown to promote ovarian cysts in premenopausal women; however, the effect of tamoxifen on ovarian cancer risk is still controversial. In the current experiment, Fischer 344 rats (n = 8 per treatment group) received tamoxifen (TAM) or vehicle (control) in factorial combination with combined breast and ovarian carcinogen (17β-estradiol and 7,12 dimethylbenza[a]anthracene, respectively). Mammary and ovarian morphologies were normal in the control and TAM groups. Carcinogen (CARC) treatment induced mammary dysplasia with elevated cell proliferation and reduced estrogen receptor- expression and promoted preneoplastic changes in the ovary. In the CARC + TAM group, tamoxifen reduced preneoplastic changes and proliferation rate in the mammary gland, but not in the ovary, compared with rats treated with carcinogen alone. Putative stem cell markers (Oct-4 and aldehyde dehydrogenase 1) were also elevated in the mammary tissue by carcinogen and this expansion of the stem cell population was not reversed by tamoxifen. Our study suggests that tamoxifen prevents early progression to mammary cancer but has no effect on ovarian cancer progression in this rat model.

Key Words: breast cancer • ovarian cancer • cancer prevention • preclinical model • tamoxifen

This article has been cited by other articles:

				T. A. Rose-Hellekant, A. J. Skildum, O. Zhdankin, A. L. Greene, R. R. Regal, K. D. Kundel, and D. W. Kundel Short-term Prophylactic Tamoxifen Reduces the Incidence of Antiestrogen-Resistant/Estrogen Receptor-Positive/Progesterone Receptor-Negative Mammary Tumors Cancer Prevention Research, May 1, 2009; 2(5): 496 - 502. [Abstract] [Full Text] [PDF]